Anavex Life Sciences price to book ratio AVXL

Market value divided by the book value of the company's net assets, since 2014.

Today, Oct 23, 2026: 1.1×
10-year median: 6.4×
Against its 10-year history: 0th; percentile: 0 is its lowest day, 100 its highest
10-year range: 1.1× to 32.5×
Peer median: 2.1×

Anavex Life Sciences' price to book ratio is 1.1× as of Oct 23, 2026.

That is below its ten-year median of 6.4×, lower than on 100% of days in the last ten years.

Over that time it ranged from 1.1× in Oct 2026 to 32.5× in Feb 2021.

The median for 10 healthcare stocks of a similar size is 2.1×.

Price to book ratio over time

median 6.4×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	1.1×	1.1×	5.0×
2025	3.4×	3.1×	10.4×
2024	8.5×	2.1×	8.5×
2023	5.4×	2.9×	6.2×
2022	5.1×	4.1×	7.8×
2021	8.7×	8.3×	32.5×
2020	13.3×	5.5×	14.8×
2019	7.0×	4.1×	12.0×
2018	3.5×	3.2×	8.3×
2017	5.9×	5.7×	30.0×
2016	24.9×	9.7×	28.0×
2015	15.0×	5.9×	56.5×
2014	1.0×	0.9×	1.5×

Against its peers

Companies in Healthcare nearest Anavex Life Sciences' size, closest first, today.

Company	Price to book ratio
AVXLAnavex Life Sciences	1.1×
KEQUKewaunee Scientific	1.3×
ICCCImmucell	3.0×
PDEXPro DEX	4.2×
PLXProtalix BioTherapeutics	2.9×
LFVNLifevantage	2.2×
NATRNatures Sunshine Products	1.3×
ELMDElectromed	4.1×
SPROSpero Therapeutics	1.5×
UTMDUtah Medical Products	1.9×
APTAlpha Pro Tech	0.9×
Peer median	2.1×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Anavex Life Sciences

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.